RxDoctor Payments DataLook up a doctor →

Susan Kreppel, NP

Nurse Practitioner · Williamsville, NYNPI 1376748640

Payments from drug & device makers

$66,621in general payments, 2019–2025

Across 720 payments — averaging $92.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$22K
  • AbbVie$16K
  • Janssen Scientific Affairs, LLC$11K
  • Gilead$8K
  • Ironwood Pharmaceuticals, Inc$3K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • plus $5K from 28 others

What the payments were for

  • Consulting fees$8131%
  • Speaking & faculty fees$48,16672%
  • Travel & lodging$3,0545%
  • Food & beverage$14,37122%
  • Education$2160%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$66,621 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$18,753
Medicare patients
152
Services billed
183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab39$1,321,073
CreonLipase/Protease/Amylase44$113,146
LinzessLinaclotide125$102,643
Mesalamine111$73,212
XifaxanRifaximin17$44,035
Alosetron Hcl22$32,604
Mesalamine ErMesalamine50$28,820
Budesonide ErBudesonide19$18,062
MotegrityPrucalopride Succinate27$16,953
NexiumEsomeprazole Magnesium13$14,652
Omeprazole665$14,630
Balsalazide Disodium60$10,330
DelzicolMesalamine12$9,989
Mesalamine DrMesalamine16$9,892
Pantoprazole Sodium460$8,983

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$21,925$1,321,07339 claims
AbbVieCreon, Linzess, Delzicol$16,262$225,777181 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$664$44,03517 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$1,334$16,95327 claims
SandozLansoprazole$35$3,282103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →